| 58.7 -0.1 (-0.17%) | 01-22 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 69.44 | 1-year : | 81.11 |
| Resists | First : | 59.45 | Second : | 69.44 |
| Pivot price | 58.93  |
|||
| Supports | First : | 58.07  |
Second : | 57.22 |
| MAs | MA(5) : | 58.77 |
MA(20) : | 58.92 |
| MA(100) : | 52.37 |
MA(250) : | 45.4 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 19.3 |
D(3) : | 22.7 |
| RSI | RSI(14): 56.1 | |||
| 52-week | High : | 64.41 | Low : | 27.29 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MRTX ] has closed above bottom band by 11.5%. Bollinger Bands are 91.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 59 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 58.84 - 59.23 | 59.23 - 59.58 |
| Low: | 57.71 - 58.22 | 58.22 - 58.68 |
| Close: | 57.93 - 58.72 | 58.72 - 59.43 |
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Fri, 19 Jan 2024
Mirati Therapeutics stock ticks higher amid Nasdaq delisting for sale to Bristol-Myers - Seeking Alpha
Mon, 25 Dec 2023
Mirati Therapeutics' CVR Value In The Wake Of The Bristol Myers Acquisition (NASDAQ:MRTX) - Seeking Alpha
Mon, 06 Nov 2023
Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates - PR Newswire
Thu, 12 Oct 2023
Biotech Stock Roundup: BMY Grabs MRTX, AKRO Down on Study Data, ALNY Faces Setback - Yahoo Finance
Mon, 09 Oct 2023
Bristol Myers (BMY) to Acquire Mirati Therapeutics for $5.8 B - Yahoo Finance
Mon, 09 Oct 2023
Bristol Myers to Buy Mirati Therapeutics for $4.8 Billion - Bloomberg
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 70 (M) |
| Held by Insiders | 3.891e+007 (%) |
| Held by Institutions | 1.7 (%) |
| Shares Short | 4,740 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.6068e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 49.1 % |
| Return on Equity (ttm) | -39.3 % |
| Qtrly Rev. Growth | 3.819e+007 % |
| Gross Profit (p.s.) | 262.33 |
| Sales Per Share | -90.85 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -12.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -594 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.65 |
| Price to Cash Flow | 3.34 |
| Dividend | 0 |
| Forward Dividend | 4.39e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|